Strategy

In many plants, the full expression of therapeutic value only emerges when their components are allowed to work in concert.

The regulatory environment has become increasingly supportive of multi-indication development.

Executives who treat capital allocation as a CEO-level strategic discipline are best positioned to thrive in a volatile and increasingly capital-constrained environment.

Both community and academic delivery models play essential and complementary roles in expanding CGT access.

Nurse practitioners and physician associates are two of the fastest growing clinician groups.

While the growing oncology pipeline offers tremendous potential, the path from clinical development through to commercial launch and patient administration is complex and lined with challenges that can impact product success and access.

Olympia Pharmaceuticals’ co-founders discuss how they’re pivoting in light of FDA’s decision.

New technologies and external factors are forcing companies to rethink financial planning and analysis.

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales producers, its 25th, points to the importance of organizations doubling down on what they do best while seizing new opportunities to innovate.

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.

35 years of manufacturer rebates by any other name.

For a growth mindset to truly take hold, leaders must create space for those possibilities to thrive.

These diseases require specialty treatment typically unavailable at local retail pharmacies or small health systems, making it extremely difficult for many patients to get the care they need.

In today’s environment, aligning the Target Product Profile with the appropriate Value Evidence Archetype is not just good practice, it is a strategic imperative.

In this Pharmaceutical Executive exclusive, Bob Jansen, David Shulkin, Gen. Paul Funk (Ret.), and Maj. Gen. Dennis LeMaster (Ret.)—members of the Federated Healthcare Advisory Panel—discuss how pharmaceutical companies can strengthen supply chain resilience, navigate policy shifts, and adopt a national security mindset.

The traditional biopharma approach focused primarily on physician detailing and securing favorable payer contracts, has become inadequate in today’s market.

Meeting the growing need and demand for fast information to make optimal and timely treatment decisions.

A well-defined scientific and strategic approach is critical for buyers in this dealmaking setting.

Identifying the priorities that translate to strong business outcomes—and separating the top performers from the average brands.

Navigating technology and regulatory shifts in pharma revenue management.

Five steps for organizations in bringing enterprise-level strategies to life.

In the face of potential tariffs, the pharmaceutical industry must find alternative ways to reduce costs.

Four tips for midsized companies when entering new global markets.

The high-stakes nature of cancer care, coupled with rapid scientific advancements and increasing payer and regulatory pressures, demands a specialized approach beyond traditional market access strategies.

Applying the McKinsey 7S Framework to TLL and regional marketing teams.

The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic portfolio management to optimize resource allocation and enhance competitive advantage.

A look at the current landscape and how young companies can set the stage for product launch.

Market dynamics boost the need and urgency for more sophisticated benchmarking strategies.

HEOR scientists in the pharma industry must balance methodologic rigor with commercial expectations and timelines.

The six key design trends of 2025 redefine how healthcare brands can inspire trust and build lasting connections with their audiences.